|
The evolving role of next generation sequencing in myelodysplastic syndromes |
Oct 2019 |
British Journal of Haematology |
Myelodysplastic Syndromes (MDS) |
|
Association of provider experience and clinical outcomes in patients with myelodysplastic syndromes receiving hypomethylating agents |
Oct 2019 |
Leukemia & Lymphoma |
Myelodysplastic Syndromes (MDS) |
|
Genomic Biomarkers to Predict Resistance to Hypomethylating Agents in Patients With Myelodysplastic Syndromes Using Artificial Intelligence |
Sep 2019 |
JCO Precision Oncology |
Myelodysplastic Syndromes (MDS) |
|
Ravulizumab: a novel C5 inhibitor for the treatment of paroxysmal nocturnal hemoglobinuria |
Sep 2019 |
Therapeutic Advances in Hematology |
Paroxysmal Nocturnal Hemoglobinuria (PNH) |
|
Germline DDX41 mutations define a significant entity within adult MDS/AML patients |
Sep 2019 |
Blood |
Myelodysplastic Syndromes (MDS) |
|
Phase 2 Study of the ALK5 Inhibitor Galunisertib in Very Low-, Low-, and Intermediate-Risk Myelodysplastic Syndromes |
Sep 2019 |
Clinical Cancer Research: an official Journal of the American Association of Cancer Research |
Myelodysplastic Syndromes (MDS) |
|
Management of aplastic anemia after failure of frontline immunosuppression |
Jul 2019 |
Expert Review of Hematology |
Aplastic Anemia |
|
Defining the Boundary Between Myelodysplastic Syndromes and Myeloproliferative Neoplasms |
Jul 2019 |
Surgical Pathology Clinic |
Myelodysplastic Syndromes (MDS) |
|
A genomics-informed computational biology platform prospectively predicts treatment responses in AML and MDS patients |
Jun 2019 |
Blood Advances |
Myelodysplastic Syndromes (MDS) |
|
Activin Receptor II Ligand Traps: New Treatment Paradigm for Low-Risk MDS |
Jun 2019 |
Current Hematologic Malignancy Report |
Myelodysplastic Syndromes (MDS) |
